These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7928673)

  • 1. Dorrigocins: novel antifungal antibiotics that change the morphology of ras-transformed NIH/3T3 cells to that of normal cells. III. Biological properties and mechanism of action.
    Kadam S; McAlpine JB
    J Antibiot (Tokyo); 1994 Aug; 47(8):875-80. PubMed ID: 7928673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dorrigocins: novel antifungal antibiotics that change the morphology of ras-transformed NIH/3T3 cells to that of normal cells. I. Taxonomy of the producing organism, fermentation and biological activity.
    Karwowski JP; Jackson M; Sunga G; Sheldon P; Poddig JB; Kohl WL; Kadam S
    J Antibiot (Tokyo); 1994 Aug; 47(8):862-9. PubMed ID: 7928671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dorrigocins: novel antifungal antibiotics that change the morphology of ras-transformed NIH/3T3 cells to that of normal cells. II. Isolation and elucidation of structures.
    Hochlowski JE; Whittern DN; Hill P; McAlpine JB
    J Antibiot (Tokyo); 1994 Aug; 47(8):870-4. PubMed ID: 7928672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
    Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
    Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
    Leftheris K; Kline T; Vite GD; Cho YH; Bhide RS; Patel DV; Patel MM; Schmidt RJ; Weller HN; Andahazy ML; Carboni JM; Gullo-Brown JL; Lee FY; Ricca C; Rose WC; Yan N; Barbacid M; Hunt JT; Meyers CA; Seizinger BR; Zahler R; Manne V
    J Med Chem; 1996 Jan; 39(1):224-36. PubMed ID: 8568812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.
    Carboni JM; Yan N; Cox AD; Bustelo X; Graham SM; Lynch MJ; Weinmann R; Seizinger BR; Der CJ; Barbacid M
    Oncogene; 1995 May; 10(10):1905-13. PubMed ID: 7761092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SCH 51344 inhibits ras transformation by a novel mechanism.
    Kumar CC; Prorock-Rogers C; Kelly J; Dong Z; Lin JJ; Armstrong L; Kung HF; Weber MJ; Afonso A
    Cancer Res; 1995 Nov; 55(21):5106-17. PubMed ID: 7585559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. v-K-ras leads to preferential farnesylation of p21(ras) in FRTL-5 cells: multiple interference with the isoprenoid pathway.
    Laezza C; Di Marzo V; Bifulco M
    Proc Natl Acad Sci U S A; 1998 Nov; 95(23):13646-51. PubMed ID: 9811854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesylamine: an inhibitor of farnesylation and growth of ras-transformed cells.
    Kothapalli R; Guthrie N; Chambers AF; Carroll KK
    Lipids; 1993 Nov; 28(11):969-73. PubMed ID: 8277827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation.
    Cox AD; Garcia AM; Westwick JK; Kowalczyk JJ; Lewis MD; Brenner DA; Der CJ
    J Biol Chem; 1994 Jul; 269(30):19203-6. PubMed ID: 8034681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased cell-substrate adhesion accompanies conditional reversion to the normal phenotype in ras-oncogene-transformed NIH-3T3 cells.
    Shumaker DK; Sklar MD; Prochownik EV; Varani J
    Exp Cell Res; 1994 Oct; 214(2):440-6. PubMed ID: 7925639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
    Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A
    Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel compound, depudecin, induces production of transformation to the flat phenotype of NIH3T3 cells transformed by ras-oncogene.
    Sugita K; Yoshida H; Matsumoto M; Matsutani S
    Biochem Biophys Res Commun; 1992 Jan; 182(1):379-87. PubMed ID: 1731795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An elaborate pathway required for Ras-mediated epigenetic silencing.
    Gazin C; Wajapeyee N; Gobeil S; Virbasius CM; Green MR
    Nature; 2007 Oct; 449(7165):1073-7. PubMed ID: 17960246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transformation of NIH/3T3 to anchorage independence by H-ras is accompanied by loss of suppressor activity.
    Tolsma SS; Cohen JD; Ehrlich LS; Bouck NP
    Exp Cell Res; 1993 Apr; 205(2):232-9. PubMed ID: 8482334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation.
    Wang IK; Lin-Shiau SY; Lin JK
    Oncology; 2000 Sep; 59(3):245-54. PubMed ID: 11053993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor.
    Kohl NE; Mosser SD; deSolms SJ; Giuliani EA; Pompliano DL; Graham SL; Smith RL; Scolnick EM; Oliff A; Gibbs JB
    Science; 1993 Jun; 260(5116):1934-7. PubMed ID: 8316833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor.
    Bustelo XR; Suen KL; Leftheris K; Meyers CA; Barbacid M
    Oncogene; 1994 Aug; 9(8):2405-13. PubMed ID: 8036025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to apoptosis induced by alkylating agents in v-Ha-ras-transformed cells due to defect in p53 function.
    Kuo ML; Chou YW; Chau YP; Huang TS
    Mol Carcinog; 1997 Apr; 18(4):221-31. PubMed ID: 9142217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.